Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

act is significantly reduced and, as the iron is retained within the product if it is not absorbed, it is expected this will significantly reduce the risk of unwanted side effects within the gastrointestinal tract.

The international, multicentre, randomised, double-blind and placebo controlled AEGIS 1 and AEGIS 2 studies will investigate the potential of ST10 as a twice-daily treatment of IDA in subjects with Ulcerative Colitis (UC) or Crohn's disease respectively where oral ferrous preparations have failed or cannot be used.  The studies are each enrolling 120 patients and will measure patients' change in haemoglobin concentration from baseline to week 12.  Initial results from both studies are expected to be reported in late 2012 and, if positive, will be promptly followed by filings of marketing authorisation applications in key pharmaceutical markets.  In addition, Shield is planning to initiate a Phase 3 study of ST10 for the treatment of IDA in patients with chronic kidney disease in 2012.  

Data provided by IMS suggests that the iron market was worth $2.4 billion in 2010, of which 55% of revenues were generated from oral iron therapies.

There are currently no curative treatments available for UC or Crohn's and so treatment options are restricted to controlling symptoms, maintaining remission and preventing relapse.  IDA in both is a chronically debilitating disorder which has a significant impact on patients' quality of life and, as a result, its treatment is an important aspect of disease management.  Characteristic symptoms of IDA include chronic fatigue, headache and subtle impairment of cognitive function.  Up to one third of subjects with UC and Crohn's suffer from recurrent anaemia, with hospitalisation required in severe cases.

About Shield Therapeutics

Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an ind
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using ... cell therapy treatments for central nervous system diseases, announced ... the NASDAQ Capital Market under the symbol "CUR." The ... NYSE MKT until the market close on July 10, ... to commence on July 13, 2015. ...
(Date:6/29/2015)... 2015   For the seventh year running, Across Health ... overall digital maturity called the Multichannel Maturometer . ... not maturing fast enough. While it,s true that technology ... overall and customers are increasingly "digital natives", pharma still ... engagement.  ...
(Date:6/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... in the management information circular dated June 1, 2015 were ... of Shareholders, held earlier today, June 26 2015. ... nominees proposed by management were elected as Directors ... next Annual Meeting of Shareholders or until their ...
(Date:6/26/2015)... ... June 26, 2015 , ... Claremont BioSolutions, LLC, a ... been integrated into a sample prep module intended to enable real-time quantitative gene ... the NASA’s WetLab-2 Project. , On June 28, 2015, SpaceX CRS-7 will launch ...
Breaking Biology Technology:Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3
... Beck and C. Schmidt, Varian, Inc. , ... Marijuana is one of the most commonly used illegal recreational drugs in ... is tetrahydrocannabinol or THC. Toxicology, forensic, and clinical labs are often asked ... of THC, most frequently the carboxy form. , ...
... BD Biosciences is pleased to introduce the BD ... (Cat. No. 558142) for the isolation of Treg cells ... isolates Treg cells in two stages. First, negative selection ... cocktail of biotinylated monoclonal antibodies that recognizes antigens expressed ...
... , Introduction ... the cell cycle is commonly used in cell biology since many pharmacological ... here an application that can be used in adherent cells and optionally ... , The cell cycle consists of ...
Cached Biology Technology:Analysis of ()-11-Nor-9-Carboxy-Delta-9-THC in Urine by Negative Ion Electrospray LC/MS/MS 2Analysis of ()-11-Nor-9-Carboxy-Delta-9-THC in Urine by Negative Ion Electrospray LC/MS/MS 3Quantitative Analysis of the Cell Cycle in Imaging Applications 2Quantitative Analysis of the Cell Cycle in Imaging Applications 3Quantitative Analysis of the Cell Cycle in Imaging Applications 4Quantitative Analysis of the Cell Cycle in Imaging Applications 5
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a ... announced that its U.are.U ® 4500 fingerprint ... Eateries, Inc., a San ... chain, to increase security, improve accountability and reduce ... enable instant, non-repudiable identity confirmation for employee sign ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue ... amount to at least 340 MSEK to that it will ... in market growth and orders received the revenue guidance for ... for 2015 will exceed 1,500 MSEK to an updated guidance ... Due to receipt of orders of touch fingerprint ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... its patent to electronically capture, analyze and identify ... facial recognition methods. This system can: ... by an enrollment and subsequent sign-on process is ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... Nature, the authors including Dr Ying ... Climate Research say that nitrogen fixation has long ... of many ecosystems particularly boreal and temperate forests ... been significant discrepancies between real-world observations and the theories ...
... has been successful in gaining major European Union ... of biological samples, such as DNA, can be ... Europe. The Centre for Integrated Genomic Medical ... Medicine, is playing a key role in developing ...
... N.Y., June 17 bioMETRX, Inc. (OTC,Bulletin Board: ... today announced that the Handgun Club of America ... are showing great interest in,bioMETRX,s smartTOUCH(TM) bioVAULT 2.0 ... with the touch of a finger, and recognition,taking ...
Cached Biology News:Scientists may have solved an ecological riddle 2Manchester clears first hurdle in €170 million biobank building boom 2bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 2bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 3